| Autor: |
Butler, Stephen F., Budman, Simon H., Licari, Andrea, Cassidy, Theresa A., Lioy, Katherine, Dickinson, James, Brownstein, John S., Benneyan, James C., Green, Traci Craig, Katz, Nathaniel |
| Zdroj: |
Pharmacoepidemiology & Drug Safety; Dec2008, Vol. 17 Issue 12, p1142-1154, 13p |
| Abstrakt: |
Purpose The National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™) is a scientific, comprehensive risk management program for scheduled therapeutics. NAVIPPRO™ provides post-marketing surveillance, signal detection, signal verification and prevention and intervention programs. Here we focus on one component of NAVIPPRO™ surveillance, the Addiction Severity Index-Multimedia Version® (ASI-MV®) Connect, a continuous, real-time, national data stream that assesses pharmaceutical abuse by patients entering substance abuse treatment by collecting product-specific, geographically-detailed information. Methods We evaluate population characteristics for data collected through the ASI-MV® Connect in 2007 and 2008 and assess the representativeness, geographic coverage, and timeliness of report of the data. Analyses based on 41 923 admissions to 265 treatment centers in 29 states were conducted on product-specific opioid abuse rates, source of drug, and route of administration. Results ASI-MV® Connect data revealed that 11.5% of patients reported abuse of at least one opioid analgesic product in the 30 days prior to entering substance abuse treatment; differences were observed among sub-populations of prescription opioid abusers, among products, and also within various geographic locations. Conclusions The ASI-MV® Connect component of NAVIPPRO™ represents a potentially valuable data stream for post-marketing surveillance of prescription drugs. Analyses conducted with data obtained from the ASI-MV® Connect allow for the characterization of product-specific and geospatial differences for drug abuse and can serve as a tool to monitor responses of the abuse population to newly developed 'abuse deterrent' drug formulations. Additional data, evaluation, and comparison to other systems are important next steps in establishing NAVIPPRO™ as a comprehensive, post-marketing surveillance system for prescription drugs. Copyright © 2008 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text